Kyorin Pharmaceutical has approved a partial revision of its equity compensation program, adding delegated executive officers as eligible participants. The document details the overview of the program, trust mechanisms, and contribution amounts, among other details.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4569-20260512-07.pdf","jir_short_summary":"Kyorin Pharmaceutical has approved a partial revision of its equity compensation program, adding delegated executive officers as eligible participants. The document details the overview of the program, trust mechanisms, and contribution amounts, among other details.","jir_summary":"### Program Overview\nKyorin Pharmaceutical has partially revised its performance-linked stock compensation program targeted at directors and delegated executive officers. The program uses monetary contributions as its funding source to acquire and grant shares through a trust mechanism. The revision enhances flexibility and transparency by adding delegated executive officers as beneficiaries and setting limits on point grants. The document also explains the detailed structure of the program and the trust management, aiming to ensure program continuity and the enhancement of corporate value.\n\n### Program Impact and Future Outlook\nThe revision of this program aims to strengthen incentivization for officers and ensure management neutrality. Expanding the scope of eligible participants is expected to motivate management and improve long-term corporate value. The trust structure and the point grant limits ensure fairness and sustainability, while maintaining alignment with the company's medium-term management plan.","jir_financial_highlights":"Contribution Amount: Unknown (Unknown)\nPoint Grant Limit: 43,000 points (25,000 points for directors) (Unknown)\nTrust Period: From August 8, 2016, until trust completion (Continuing since program start)","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #EquityCompensationRevision, #JapanStocks","jir_key_figures":"Contribution Amount: Unknown\nPoint Grant Limit: 43,000 points (25,000 points for directors)\nTrust Period: From August 8, 2016, until program termination","jir_meta_title":"\u3010Kyorin Pharmaceutical\u3011 Equity Compensation Program Revision | May 2026","jir_meta_description":"Kyorin Pharmaceutical has approved a partial revision of its equity compensation program, detailing added eligible participants and point limits. Strengthening long-term incentives.","jir_og_title":"\u3010Kyorin Pharmaceutical\u3011 Equity Compensation Program Revision | May 2026","jir_og_description":"Kyorin Pharmaceutical announces a partial revision of its equity compensation program. Details of added eligible participants, point limits, and future outlook are explained.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-48162","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n